Large-cap Health Care company Sanofi has moved 3.7% so far today on a volume of 5,106,431, compared to its average of 2,321,582. In contrast, the S&P 500 index moved -0.0%.
Sanofi trades -17.17% away from its average analyst target price of $59.12 per share. The 5 analysts following the stock have set target prices ranging from $55.0 to $65.0, and on average have given Sanofi a rating of buy.
Anyone interested in buying SNY should be aware of the facts below:
-
Sanofi's current price is -35.1% below its Graham number of $75.42, which implies the stock has a margin of safety
-
Sanofi has moved -11.7% over the last year, and the S&P 500 logged a change of 26.2%
-
Based on its trailing earnings per share of 1.94, Sanofi has a trailing 12 month Price to Earnings (P/E) ratio of 25.2 while the S&P 500 average is 27.65
-
SNY has a forward P/E ratio of 10.1 based on its forward 12 month price to earnings (EPS) of $4.87 per share
-
The company has a price to earnings growth (PEG) ratio of 1.27 — a number near or below 1 signifying that Sanofi is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 0.83 compared to its sector average of 3.61
-
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.
-
Based in Paris, the company has 86,088 full time employees and a market cap of $122.87 Billion.